For Biotechs, a bright future with challenges

Live from BIO: For Biotechs, a bright future with challenges

At the first day of BIO 2008 conference I met with Murry Aitken, Senior VP of Healthcare Insight at IMS Health. IMS just released a report on the growth of biologic drugs in 2007. Global biologic sales increased 12.5 percent in 2007 to more than $75 billion; that's twice as fast as the pharmaceutical market, which increased 6.4 percent in 2007.

The future is looking rosy for biotech, but that doesn't mean that biotechs can go about their business without an eye on the future. The most obvious eventual challenge for biologics are biosimilars--generic versions of biotech drugs. More immediately, however, biotechs must address issues of safety versus costs. Biotech's ability to forsee and prepare for the future will help it avoid some of the problems Big Pharma is facing now. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.